Medication Adherence in Children and Adults Receiving Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Sweden: A Nationwide Study
Journal of Attention Disorders · 2026
DOI: 10.1177/10870547251406760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Attention Disorders, 2026. Verfasst von MaiBritt Giacobini und 5 weiteren Autor:innen. Beteiligte Einrichtung: PRIMA Järva, Spånga, Sweden. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Drug Monitoring, Registries. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shire Development LLC, takeda pharmaceuticals international.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
To estimate the adherence of children and adults to oral stimulant ADHD treatments in Sweden during the period 2015 to 2020.
Methods
This retrospective, nationwide, register-based study evaluated all patients who were dispensed oral formulation stimulants (Anatomical Therapeutic Chemical [ATC] codes: N06BA01, N06BA02, N06BA04, N06BA12) identified in the Swedish Prescribed Drug Register. Treatment episodes were constructed based on drug dispensation data, and treatment adherence was calculated for each treatment episode using a Proportion of Days Covered approach with a modified one-pill-a-day method.
Results
Between 2015 and 2020, 158,413 treatment episodes were recorded in 128,366 patients, corresponding to a median 1.23 treatment episodes per patient. The majority of treatment episodes involved methylphenidate (64.0%), followed by lisdexamfetamine (32.2%), dexamfetamine (3.0%), and amphetamine (0.8%). Overall treatment adherence was high (78.2%), and was similar for patients receiving methylphenidate, lisdexamfetamine, and dexamfetamine. The proportion of patients with ≥80% medication adherence was high (69.3%–71.8%) for adults aged ≥25 years, but was low for adolescents aged 12 to 17 years (49.7%–52.4%).
Conclusions
The overall rates of treatment adherence are high for children and adults receiving ADHD medication in Sweden. We observed lower adherence among adolescents, which warrants further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PRIMA Järva, Spånga, Sweden.
- Karolinska Institutet, Stockholm, Sweden.
- Parexel International, Stockholm, Sweden.
- Umeå University, Sweden.
- Takeda Pharma AB, Stockholm, Sweden.
- Northern Stockholm Psychiatry, Sweden.
ORCID-Profile: MaiBritt Giacobini
Förderung
- Shire Development LLC
- takeda pharmaceuticals international
Zitieren
APA
Giacobini, M., Zhao, J., Freilich, J., Brünner, C., Wallin Bernhardsson, N., & Ahnemark, E. (2026). Medication Adherence in Children and Adults Receiving Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Sweden: A Nationwide Study. Journal of Attention Disorders. https://doi.org/10.1177/10870547251406760
Vancouver
Giacobini M, Zhao J, Freilich J, Brünner C, Wallin Bernhardsson N, Ahnemark E. Medication Adherence in Children and Adults Receiving Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Sweden: A Nationwide Study. Journal of Attention Disorders. 2026. doi:10.1177/10870547251406760
BibTeX
@article{Giacobini2026,
author = {Giacobini, MaiBritt and Zhao, Jingcheng and Freilich, Jonatan and Brünner, Carolina and Wallin Bernhardsson, Niklas and Ahnemark, Ewa},
title = {Medication Adherence in Children and Adults Receiving Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Sweden: A Nationwide Study},
journal = {Journal of Attention Disorders},
year = {2026},
doi = {10.1177/10870547251406760}
}
EUVIMED